Document
IPR2022-00855, No. 2041-87 Exhibit - Renier J Brentjens et al, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, 13 CLINICAL CANCER RSCH 5426 2...
Cite Document
IPR2022-00855, No. 2041-87 Exhibit - Renier J Brentjens et al, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, 13 CLINICAL CANCER RSCH 5426 2007 (P.T.A.B. Jul.
+ More Snippets
Document
IPR2022-00855, No. 2011-57 Exhibit - Brian G Till et al, Adoptive immunotherapy for indolent non Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20 spec...
Cite Document
IPR2022-00855, No. 2011-57 Exhibit - Brian G Till et al, Adoptive immunotherapy for indolent non Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20 specific T cells,
+ More Snippets
Document
IPR2022-00855, No. 2022-68 Exhibit - Holly Auer, Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize, PENN TODAY Mar 11, 201...
Cite Document
IPR2022-00855, No. 2022-68 Exhibit - Holly Auer, Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize, PENN TODAY Mar 11, 2015 (P.T.A.B. Jul. 19,
+ More Snippets
Document
IPR2022-00855, No. 2002-48 Exhibit - Denise Grady, An Immune System Trained to Kill Cancer, NY TIMES Sept 12, 2011, httpswwwnytimescom20110913health13genehtml (P.T.A.B. Jul. 19, 20...
Cite Document
IPR2022-00855, No. 2002-48 Exhibit - Denise Grady, An Immune System Trained to Kill Cancer, NY TIMES Sept 12, 2011, httpswwwnytimescom20110913health13genehtml (P.T.A.B. Jul. 19, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2016-62 Exhibit - Jennifer Couzin Frankel, Breakthrough of the Year 2013 Cancer Immunotherapy, 342 SCI 1432 2013 (P.T.A.B. Jul. 19, 2022)
Cite Document
IPR2022-00855, No. 2016-62 Exhibit - Jennifer Couzin Frankel, Breakthrough of the Year 2013 Cancer Immunotherapy, 342 SCI 1432 2013 (P.T.A.B. Jul. 19, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2013-59 Exhibit - Renier Brentjens et al, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells case report of an unforeseen adverse event ...
Cite Document
IPR2022-00855, No. 2013-59 Exhibit - Renier Brentjens et al, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells case report of an unforeseen adverse event in a phas
+ More Snippets
Document
IPR2022-00855, No. 2006-52 Exhibit - Denise Grady, FDA Approves First Gene Altering Leukemia Treatment, Costing $475,000, NY TIMES Aug 30, 2017, httpswwwnytimescom20170830health...
Cite Document
IPR2022-00855, No. 2006-52 Exhibit - Denise Grady, FDA Approves First Gene Altering Leukemia Treatment, Costing $475,000, NY TIMES Aug 30, 2017, httpswwwnytimescom20170830healthgene therapy cancerhtml
+ More Snippets
Document
IPR2022-00855, No. 2025-71 Exhibit - Agilent Presents Thought Leader Award to Drs Carl H June and Michael Milone, AGILENT TECHS INC Nov 17, 2020, httpswwwagilentcomaboutnewsroomp...
Cite Document
IPR2022-00855, No. 2025-71 Exhibit - Agilent Presents Thought Leader Award to Drs Carl H June and Michael Milone, AGILENT TECHS INC Nov 17, 2020, httpswwwagilentcomaboutnewsroompresrel202017nov ca2003
+ More Snippets
Document
IPR2022-00855, No. 2035-81 Exhibit - Grazyna Lipowska Bhalla, Targeted immunotherapy of cancer with CAR T cells achievements and challenges, 61 CANCER IMMUNOLOGY, IMMUNOTHER...
Cite Document
IPR2022-00855, No. 2035-81 Exhibit - Grazyna Lipowska Bhalla, Targeted immunotherapy of cancer with CAR T cells achievements and challenges, 61 CANCER IMMUNOLOGY, IMMUNOTHERAPY 953 2012 (P.T.A.B. Jul.
+ More Snippets
Document
IPR2022-00855, No. 2033-79 Exhibit - Richard A Morgan et al, Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Reco...
Cite Document
IPR2022-00855, No. 2033-79 Exhibit - Richard A Morgan et al, Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB
+ More Snippets
Document
IPR2022-00855, No. 2018-64 Exhibit - David L Porter et al, Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 CTL019 In Patie...
Cite Document
IPR2022-00855, No. 2018-64 Exhibit - David L Porter et al, Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 CTL019 In Patients With Rel
+ More Snippets
Document
IPR2022-00855, No. 2029-75 Exhibit - Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma CART 19, CLINICALTRIALSGOV April 29, 2009, httpwe...
Cite Document
IPR2022-00855, No. 2029-75 Exhibit - Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma CART 19, CLINICALTRIALSGOV April 29, 2009, httpwebarchiveorgweb200909
+ More Snippets
Document
IPR2022-00855, No. 2042-88 Exhibit - US Patent No 7,402,431 (P.T.A.B. Jul. 19, 2022)
Cite Document
IPR2022-00855, No. 2042-88 Exhibit - US Patent No 7,402,431 (P.T.A.B. Jul. 19, 2022)
+ More Snippets
Document
IPR2022-00855, No. 2041-87 Exhibit - Renier J Brentjens et al, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, 13 CLINICAL CANCER RSCH 5426 2...
Cite Document
IPR2022-00855, No. 2041-87 Exhibit - Renier J Brentjens et al, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, 13 CLINICAL CANCER RSCH 5426 2007 (P.T.A.B. Jul.
+ More Snippets
Document
IPR2022-00855, No. 2033-79 Exhibit - Richard A Morgan et al, Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Reco...
Cite Document
IPR2022-00855, No. 2033-79 Exhibit - Richard A Morgan et al, Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB
+ More Snippets